Merz and Teijin Announce Partnership to Bring Xeomin® (incobotulinumtoxinA) to Japan
Merz, a global leader in aesthetics and neurotoxins, and Teijin Limited, a technology-driven global group operating in the fields of materials, healthcare, and IT businesses, announced today that they have entered into a strategic license and co-development agreement for the commercialization of Xeomin® (incobotulinumtoxinA) for Japan.
“We believe Xeomin® will become the core product of the Teijin Group’s healthcare business, which aims to provide a total solution for stroke patients with the synergistic effects of our stroke related products and pipeline such as rehabilitation devices and regenerative medical products, “ said Akihisa Nabeshima, President, Teijin Pharma Limited. “We are extremely pleased to be establishing a partnership with Merz, whose long, successful history in neurotoxins focus shows a good strategic fit with our own.“
“In Teijin, Merz has found an exceptionally strong partner whose strength in both neurology and the rehabilitation space demonstrates an excellent strategic fit with Merz’s neurotoxin focus,” said Philip Burchard, CEO – Merz. “We are very pleased to enter this collaboration with Teijin in this highly important market, which we hope will enable us to bring neurotoxin therapy to additional patients and fulfill a key need in Japan.”
Xeomin® (incobotulinumtoxinA) was approved for use in the treatment of patients with dystonia and blepharospasm by the European regulatory authorities in 2005 and by the U.S. FDA in 2010. The product has been approved for post-stroke spasticity of the upper limb in Europe since 2009, with FDA approval for the adult upper limb spasticity indication granted in 2015. Xeomin® (incobotulinumtoxinA) is marketed in 50 countries around the world. Merz uses state-of-the-art technology in its dedicated, FDA-approved facility in Dessau, Germany, meeting the highest international standards for biologic manufacturing.
Under the terms of the agreement, Merz will receive an upfront payment in addition to milestones and royalties. Merz is currently sponsoring two clinical trials in Japan covering spasticity of both upper and lower limbs, and the upper limb trial is expected to be completed in 2018. Teijin Pharma Limited, the core company of Teijin Group’s healthcare business will prepare and file the marketing approval application. Upon the marketing approval of Xeomin® (incobotulinumtoxinA), Merz will be responsible for the product manufacturing and supply and Teijin Pharma will manage commercial activities in Japan.
“Merz has a long history of successful partnerships both in Japan and around the world, and we continue to actively seek opportunities to collaborate with well-matched strategic partners such as Teijin,” said Jörg Bergler, Global Head of Corporate Development for Merz. “Teijin Pharma is a growing player within rehabilitation in Japan, and has shown a strong track record of product maximization and market expansion in their Pharmaceutical business, and Merz looks forward to a productive and successful relationship with them for many years to come.”
With approximately 3,000 employees and 34 subsidiaries, Merz is a leading global provider in the fields of Aesthetics and Neurotoxins. Privately held for more than 100 years, the company is distinguished by its in-house research and development, solid financial strength and continuous growth. In addition to its unique portfolio of products for minimally invasive and non-invasive skin rejuvenation and tightening, Merz also develops neurotoxin therapy to treat neurologically induced movement disorders. OTC medicines, dietary supplements and skincare products round off the offerings from the company, which is headquartered in Frankfurt, Germany. In fiscal year 2015/16, the Merz Pharma Group generated revenue of EUR 1,092.9 million. More information is available at www.merz.com.
About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the areas of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Its main fields of operation are high-performance fibers such as aramid, carbon fibers & composites, healthcare, films, resin & plastic processing, polyester fibers, products converting and IT. The group has some 170 companies and around 19,000 employees spread out over 20 countries worldwide. It posted consolidated sales of JPY741.3 billion (USD 6.5 billion) and total assets of JPY 964.1 billion (USD 8.5 billion) in the fiscal year ending March 31, 2017. Please visit www.teijin.com .
Merz Pharma GmbH & Co. KGaA
Global Corporate Communications
Mariana Smith Bourland
Phone: +49 151 4249 1466
Phone: +81 3 3506 4055
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Pacific Drilling Announces Settlement in Mediation Between Quantum Pacific and Ad Hoc Group of Creditors20.8.2018 14:02 | Pressemelding
Pacific Drilling S.A. (OTC:PACDQ) (“Pacific Drilling” or the “Company”) today announced that its plan of reorganization filed on July 31, 2018 (the “Plan”), based on a proposal presented to the Company’s Board of Directors by an ad hoc group of its secured creditors (collectively, the “Ad Hoc Group”), now has the full support of the Company’s majority shareholder, Quantum Pacific (Gibraltar) Limited (“QP”). The Plan was already supported by all of the Company’s major creditor interests. With QP’s participation, the Company expects a smooth plan confirmation process and a quick emergence from its Chapter 11 proceedings. Pacific Drilling CEO Paul Reese commented, “The agreement reached by QP and the Ad Hoc Group delivers the final piece needed to make the Company’s Plan a consensual one that has the support of the Company’s major stakeholders. The agreement should allow the Plan to move forward efficiently and expeditiously through the implementation and confirmation process.” Pursuant t
Bella Hadid Headlines True Religion’s Latest Campaign20.8.2018 12:32 | Pressemelding
True Religion has tapped Bella Hadid to be the face of the brand. The supermodel embodies all things True Religion, past, present and future; iconic, edgy and everlasting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180820005283/en/ Bella Hadid Headlines True Religion’s Latest Campaign (Photo: Business Wire) An inherit fan of the brand, Bella was the natural choice to meld the iconic essence of the brand with the modern view of its future. An all-star team was assembled including photographer Boo George, stylist Mimi Cuttrell, and hair and makeup duo Jen Atkin and Mary Phillips to create imagery and complementary looks that usher True Religion into a new era that honors the heritage of the brand. A quintessential, confident LA girl with roots at home and abroad, Bella’s voice was not only an inspiration, but an integral part in imagining this campaign, envisioning the brand through her eyes for the next generation of True
Veristat Congratulates Alnylam on the FDA Approval of ONPATTRO™ (patisiran)20.8.2018 11:30 | Pressemelding
Veristat, a full service Clinical Research Organization (CRO), congratulates Alnylam on the recent FDA approval of ONPATTRO™ (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. “On behalf of the entire Veristat team that has supported Alnylam in the development of this therapy, we are humbled to have contributed towards this first-in-class drug approval for Alnylam, for the patients with hATTR amyloidosis and their families,” said John P. Balser, Ph.D., President and Co-Founder of Veristat. “We are continuing to support Alnylam as they look to expand regulatory approval of this treatment to other regions of the world.” Veristat began working with Alnylam over 11 years ago and helped design the studies and prepare the Investigational New Drug (IND) submission for patisiran. Our collaboration continued throughout the entire patisiran program inclusive of a phase 2 study, a phase 3 pivotal study
FRISS Brings Claim Fraud Analysis to a Next Level With Web-IQ´s Innovative Online Network Solution20.8.2018 11:30 | Pressemelding
Asking your neighbor or friend to sign as a witness to a claim for car damages at your insurance company will work no more, with the new Claim Fraud Analysis feature of FRISS. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180820005039/en/ Eldert van Wijngaarden (Web-IQ) and Philip van Waning (FRISS) shaking hands. (Photo: Business Wire) FRISS, the worldwide provider of AI powered fraud and risk solutions for the P&C insurance industry, recently added a new and innovative feature in their fraud analytics solution: Online Network Analysis from Web-IQ. This feature automatically identifies if the claimants and the insured or other involved persons are related to each other in an on-line environment. This is a proven and strong indicator for fraudulent claims. Especially with car accidents and other types of claims where multiple persons are involved, it adds a whole new approach to the traditional claim analyses. “Research sho
Global IBC Future Zone and IABM Future Trends Theatre to Explore the Latest Tech Shaping the Industry20.8.2018 11:18 | Pressemelding
IBC2018, the world’s most influential media, entertainment and technology show, today announces the line-up for the IBC Future Zone and IABM Future Trends Theatre. Well established as part of the IBC Exhibition, from 14-18 September, the Future Zone brings together the very latest ideas, innovations and concept technologies from international industry and academia and showcases them in a single specially-curated area sitting alongside exhibition Hall 8. This year, the focus is on showing how new technologies grow from their first inception and progress through to research, development, and validation projects; right through to maturing into the ground-breaking applications and future product standards. Major industry trail-blazers presenting their visions of the future, include Japan’s NHK and BBC R&D from the UK. Both companies will demonstrate a number of technology advances, including: Web-VR applications; object-based media scenarios; pathways to 8K resolution for UHD; and Artifici
Ocean Ambassador of the Netherlands Joins Endowment for Clean Ocean’s Entrepreneur Judges Committee20.8.2018 11:07 | Pressemelding
The Endowment for Clean Oceans (ECO) announced Willemijn Peeters, Ocean Ambassador of the Netherlands and the Founding Director of Searious Business has joined ECO’s Entrepreneur Committee that will vet contestants’ plans to remove macro and micro plastics from the world’s oceans. “I am working to solve the problem of what to do with the plastic once it is removed from the ocean, by helping to create a market for plastic recovered from the ocean,” said Peeters. “Just like we need to end the use of single use plastic, we need to replace the manufacture of virgin plastic and replace it with recycled plastics, and as much as possible needs to be plastic recovered from the ocean.” View source version on businesswire.com: https://www.businesswire.com/news/home/20180820005004/en/ Contact information The Endowment for Clean Oceans Daniel Perrin Daniel.Perrin@endowmentforcleanoceans.org or firstname.lastname@example.org